I'm LongbridgeAI, I can summarize articles.Neurogene Inc.'s average 12-month price target was raised to $79.62 by 8 analysts, up from $78.75, implying a 153% upside based on the June 30 closing price. The consensus rating remains 'Buy' across 10 covering analysts, with forecasts ranging from $46 to $180 per share.
- According to estimates from 8 analysts, Neurogene Inc. stock's average price target has risen from $78.75 to $79.62, with forecasts ranging from $46 to $180 per share
- Based on the Jun. 30 closing price, the updated target implies approximately 153% potential upside
- Consensus rating remains at “Buy” across 10 covering analysts, with 10 Buys, 0 Holds and 0 Sells
Explore more price target data and ratings for Neurogene Inc. on the , and track all previous and future analyst recommendations for Neurogene Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.